Results 151 to 160 of about 6,101 (249)

Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study

open access: hybrid, 2022
Lauren Elman   +13 more
openalex   +2 more sources

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy [PDF]

open access: yes, 2023
Baumann, Matthias   +39 more
core   +1 more source

JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam [PDF]

open access: yes
Risdiplam is a once-daily oral, survival of motor neuron 2 (SMN2) splicing modifier approved for the treatment of spinal muscular atrophy (SMA). JEWELFISH (NCT03032172) investigated the safety, tolerability, pharmacokinetics (PK), and PK/pharmacodynamic (
Bruno, Claudio   +15 more
core  

CO108 Longitudinal Trends in Hospitalization Rates in Patients with Later-Onset Spinal Muscular Atrophy (SMA) Treated with Nusinersen up to 4.5 Years: Results from the Cherish and Shine Studies

open access: bronze, 2023
Tao Jiang   +8 more
openalex   +1 more source

Home - About - Disclaimer - Privacy